Biogen Inc. (BIIB) Earnings Call Transcript & Summary

February 3, 2022

NASDAQ US Health Care Biotechnology earnings 66 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Hello everyone, and thanks for joining us for Biogen's Q4 2021 results discussion. First off, I'd suggest visiting the investor area on biogen.com, where you can access the earnings announcement and accompanying financial tables — this includes our GAAP figures and a bridge from GAAP to the non-GAAP metrics we'll be covering today. Tables 1 and 2 contain our GAAP financials, while table 4 provides a reconciliation between GAAP and non-GAAP results. In our view, non-GAAP results give a clearer picture of the underlying economics of the company and match how we steer things internally. Slides are also available on our site that align with the topics we'll address on this call. I want to note that today's remarks will include forward-looking statements grounded in what we currently expect and believe; such statements carry specific risks and uncertainties, so actual outcomes could differ significantly. For more information, please review the risk factors outlined in our SEC filings. On this call, we'll cover Aduhelm. Aduhelm is approved to treat Alzheimer's disease. Patients who begin Aduhelm should be those experiencing mild cognitive impairment or the mild dementia phase of the illness — the same group that received treatment during clinical trials. We lack safety or efficacy information for starting therapy at earlier or later disease stages than those that were studied. This indication was granted under accelerated approval, based on decreases in amyloid beta plaques seen among patients given Aduhelm. Keeping this approval could depend on confirming clinical benefit through a confirmatory trial or trials. Serious side effects, such as amyloid-related imaging abnormalities, or ARIA, may occur with Aduhelm. Though typically symptom-free, ARIA is a frequent side effect that has the potential to become serious. Severe allergic responses can also result from Aduhelm. ARIA, headache, and fall are among the most frequently reported side effects. Full prescribing details and the patient medication guide can be found at aduhelm.com. Joining me today are our Chief Executive Officer, Michel Vounatsos, Dr. Priya Singhal, Interim Head of Research and Development, and our CFO, Mike McDonnell. For the Q&A segment, Alisha Alaimo, who leads our U.S. organization, will also be with us. One last reminder — when we get to Q&A, please keep to a single question per person. I'll hand things over now to Michel.

Michel Vounatsos

executive
#2

Hello, everyone, and thanks for being with us today. I'll begin with a quick look at how we performed financially, then Mike will walk through further specifics. During the fourth quarter, revenue at Biogen came to roughly $2.7 billion, which was down 4% compared with the same period a year earlier, reflecting continued erosion of U.S. Tecfidera revenue stemming from generic competition. Non-GAAP earnings per share for Q4 2021 reached $3.39. In our view, these results demonstrate that Biogen can execute effectively. That said, in light of several difficulties encountered lately, we are announcing cost-cutting actions that should produce roughly $500 million in annualized savings, and Mike will share more information on that. I'd now like to comment briefly on the proposed national coverage determination, or NCD, covering the class of anti-amyloid monoclonal antibodies indicated for Alzheimer's disease treatment. In its present form, the draft NCD requires coverage with evidence development, or CED, meaning reimbursement would go only to Medicare beneficiaries who enroll in an approved randomized controlled trial. In formulating this draft recommendation, the Centers for Medicare & Medicaid Services, or CMS, pointed to three main areas of concern regarding this therapy class, each carrying implications for Aduhelm. To begin with, CMS sees gaps in the clinical benefit data for these therapies. Next, CMS thinks further information is necessary concerning the possible risks associated with removing amyloid, chiefly ARIA. Finally, CMS wants more data gathered on underrepresented communities, where Alzheimer's disease occurs more often; these same areas matter to Biogen, where numerous key initiatives are already in motion; we remain dedicated to constructive dialogue with CMS to resolve their issues, and we share CMS's view that extra data could help further define the benefit-risk profile for this therapy class. Since the FDA has now granted Aduhelm approval, our position is that the most useful data generation can truly come only through broader drug use in real-world settings. We likewise concur with CMS that the ultimate NCD ruling ought not to duplicate work already underway. Taking the proposal as it's written right now, our read is that the draft CD mandates would be prohibitive for patients, far too onerous, costly for companies, and duplicative of information that ongoing trials along with the FDA's existing post-marketing requirements are going to generate. In our judgment, the best way to address CMS's concerns is to build on what the Aduhelm phase III trials found — those trials gave us data covering more than 3,000 patients — using a strategy with several fronts: the phase IV confirmatory study ENVISION, our EMBARK redosing study, which has enrolled roughly 1,700 patients, the ongoing ICARE AD registry, continuing phase III trials of other antibodies in the class, and further planned efforts to generate real-world data. We believe this substantial opportunity to collect data will completely resolve whatever uncertainty remains regarding the clinical effectiveness and safety profile of treatments that lower amyloid beta; in that vein, we expect to begin screening patients for the ENVISION study during May of this year, and the primary completion date should land approximately four years afterward. This trial is designed to be placebo-controlled and conducted on a global basis, aiming to enroll 1,500 patients who have MCI resulting from Alzheimer's disease or mild Alzheimer's disease, together with confirmed amyloid beta pathology. CDR-Sum of Boxes at 18 months will serve as the planned primary endpoint, and a long-term extension lasting as long as 48 months is also planned. We think this study, taken together with the other studies I mentioned, ought to resolve the questions CMS raised. So we will keep advocating for an NCD that gives patients rapid and equitable access by covering only those patients identified as most appropriate for treatment under our FDA-approved label, which largely matches the population in our phase III clinical trial. Sorry. We also think this multi-pronged approach will make access more equal across all communities. We are concerned that the restrictions in the proposed CED would unfairly shut out access for patients in underserved communities and in geographically remote areas. On the other hand, two efforts are anticipated to help: ENVISION, plus our ICARE AD registry. That registry intends to sign up up to 6,000 people, so that data drawn from these communities becomes more representative; the goal is for 16%-18% of U.S. enrollees to come from Black and Hispanic populations. To sum up, we'll advocate for a final NCD that strikes a stronger balance — on one side, patients being able to obtain an FDA-approved treatment now, and on the other, the desire for more data, which can only be gathered gradually and as real-world use of the drug grows. We're eager to discuss this matter with CMS and to move toward a final ruling that puts patients' interests first. Past the NCD discussion from the prior quarter, we shared further results from the phase III trial of Aduhelm, which demonstrated how the therapy affects tau biology downstream in Alzheimer's, along with the link between reductions in plasma p-tau and slower cognitive and functional deterioration. We also had our phase III ARIA data published in JAMA Neurology. Going forward, our goal is to grow both inside neuroscience and outside it, guided by four pillars meant to fuel growth and create value. To start, we plan to leverage our solid neuroscience base, an area where 26 clinical development programs are currently underway. Next, we consider ourselves to hold two strong phase III programs in lupus. The risk dynamics in this therapeutic space differ from what we're used to, and we're still looking at further possibilities within specialized immunology. Moving to my third point: across the past few years, we've established a highly effective new operation around our biosimilars. Recently, we announced an agreement to exit our stake in the Samsung Bioepis joint venture by selling it to Samsung Biologics, and Biogen will remain in its current role—acting as the commercialization partner for the anti-TNF portfolio from Samsung Bioepis as well as the ophthalmology programs; as of now, we anticipate closing this deal sometime in mid-2022. After completion, moving forward, our capacity to advance the biosimilars business independently will be greater, since our goal is to deliver additional biosimilar products to a larger number of patients across more geographic regions. Mike is going to share further specifics. Finally, we're likewise concentrating on speeding up our work in digital health to bolster our commercial and pipeline programs, and at the same time to open up possibilities for potential digital therapeutics. On that note, a committed digital health portfolio has been assembled by us, and it encompasses the newly announced collaboration with TheraPanacea, intended to harness our substantial database along with machine learning and artificial intelligence, so as to create digital health solutions that could enhance patient care, hasten drug development, and deepen comprehension of underlying pathologies. Thanks to the advances we've made in these four pillars, we see the possibility of two forthcoming waves of growth, as we introduce products in new therapeutic areas and establish new franchises. To begin with, within the coming several years, we think considerable potential exists for us in Alzheimer's disease and depression—two major therapeutic areas where needs remain substantial and unmet. On the Alzheimer's front, we possess an extensive portfolio of programs, both clinical and pre-clinical, that leverage a range of modalities and targets and span amyloid as well as tau. Between Aduhelm and lecanemab, Biogen and Eisai jointly control two of the four anti-amyloid antibody treatments that have either won approval or are in late-stage development.

Michel Vounatsos

executive
#3

When it comes to depression, we're working alongside Sage Therapeutics on zuranolone, and we think this could deliver a meaningful new choice for people dealing with major depressive disorder as well as postpartum depression. Our second future waves of growth, which we expect during the mid- to late 2020s, should come from a range of different therapeutic areas — stroke, Parkinson's disease, and lupus among them — and several of these programs are already in phase III. Those expected future waves of growth will rest on our diversified pipeline, which right now has 32 clinical programs, and 10 of those sit in phase III or V. Beyond our core business, we're also glad to have exercised an option recently for mosunetuzumab, a late-stage investigational bispecific antibody that targets CD20 and CD3 and is being developed by Genentech for oncology and potentially other indication. By exercising this option, Biogen gets a private share, while Genentech will take the lead on strategy and implementation, with an FDA filing expected in the near future. This continues the long, productive collaboration between Biogen and Genentech, which started with rituximab. During 2022, our focus will stay on execution and agility, since we anticipate a number of important milestones; among them are the ongoing launch of Aduhelm in the U.S., the launch of Imraldi in the E.U., and our planned entry into the U.S. biosimilars market with BYOOVIZ. We're expecting five data readouts, three of which are in phase III, plus the completion of three regulatory filings in Alzheimer's disease, depression, and biosimilars. Before handing the call to Priya for an update on our R&D progress, I want to say first how impressed I've been by what I've seen from Priya — both as head of safety and regulatory science and, most recently, as our acting head of R&D. Her leadership ability, her strategic thinking, and her subject matter expertise leave me with the utmost confidence that she can advance our pipeline while we work to name a permanent successor. Please go ahead, Priya.

Priya Singhal

executive
#4

Thanks, Michel, and good morning to all of you. To start, I'd like to express how privileged I feel to step into the acting head of R&D position at Biogen. This company has demonstrated a history of creating therapies that transform lives in MS and SMA. Thanks to a pipeline that is both deep and varied, Biogen's goal is to deliver meaningful treatments to patients dealing with neurological and immunological conditions marked by considerable unmet need. Since this marks my initial earnings call in this capacity, I'd like to walk through several areas that excite me in particular. To begin, we see a distinctive chance for Biogen to take a leading position in Alzheimer's disease, not just because our Alzheimer's pipeline is among the industry's best, but also owing to the deliberate emphasis we've put on generating additional data continuously for aducanumab; that covers ENVISION, the phase IV post-marketing study we have planned, the ongoing EMBARK re-dosing trial, and real-world data collection via the ICARE AD registry. In our view, information from patients who received aducanumab in real-world settings with higher levels of drug utilization represents the ideal complement to the substantial clinical data amassed on aducanumab so far, alongside the clinical trials that are underway and planned. We're also still drawing possible insights about Alzheimer's disease biology and aducanumab's treatment effect from the phase III clinical data on aducanumab. On that specific topic, at last November's annual CTAD meeting, Biogen shared additional findings from the ENGAGE and EMERGE phase III trials. This important data analysis revealed that beyond lowering amyloid plaques in the brain, treatment with aducanumab additionally produced shifts in downstream tau Alzheimer's disease biology — specifically soluble phospho-tau, or p-tau, observed in both CSF and plasma; within this analysis, we examined more than 7,000 plasma samples drawn from over 1,800 subjects in the EMERGE and ENGAGE phase III trials to look into how aducanumab treatment affects plasma p-tau181. Findings demonstrated a reduction in p-tau181 that was both time and dose-dependent across 78 weeks of aducanumab treatment in the two phase III trials. From baseline to week 78 in this analysis, the decrease in plasma p-tau181 was significantly correlated with amyloid PET change during that same period, and was likewise significantly linked to less clinical decline across every primary and secondary outcome measure evaluating cognition and function in both studies. Such findings align with the hypothesis that aggregated forms of amyloid could mediate soluble tau phosphorylation. Turning to our AD pipeline, lecanemab has us enthusiastic — our other anti-amyloid antibody for Alzheimer's disease, which we're developing together with Eisai; during phase II, lecanemab didn't employ a titration period, showed rapid and robust amyloid plaque reduction, and displayed an ARIA incidence of approximately 10%. We anticipate the phase III readout in this year's second half. Past our amyloid-targeting program, we're additionally pursuing a multimodality strategy aimed at other targets in Alzheimer's. To begin, take BIIB080. This is an antisense oligonucleotide, and our belief is that it helps break down tau mRNA. In phase I, it showed reductions in CSF phospho-tau and total tau that depended on both time and dose. We expect to kick off the phase II trial of BIIB080 by the middle of this year. Next, we're preparing to launch a phase I trial soon for BIIB113, a small molecule that inhibits O-GlcNAcase, or OGA. This enzyme is thought to drive removal of the O-GlcNAc post-translational modification on tau protein. According to evidence, O-GlcNAcylation of tau lessens aggregation. Through OGA inhibition, our goal is to boost tau's O-GlcNAcylation, which could potentially block tau aggregation and in turn slow clinical decline. Since we created the first therapy approved by the FDA targeting a defining pathology of Alzheimer's, we feel Biogen holds a unique position — with the right know-how, background, and access to modalities — to lead in Alzheimer's disease. This disease is complex and calls for a multifaceted strategy plus ongoing investment as we seek to build on what we learned scientifically from Aduhelm and create the next wave of possible Alzheimer's treatments. Now I'd like to turn to depression. With its novel mechanism of action, zuranolone may, I believe, offer a significant new option for patients dealing with major depressive disorder and postpartum depression. The clinical data reported so far, drawn from numerous trials, demonstrated the following. One, in earlier trials, betterment of depressive symptoms appeared by day three. Two, zuranolone has shown a steady safety and tolerability profile, with no evidence seen of weight gain, sexual dysfunction, euphoria, or heightened suicidal ideation. Three, the SHORELINE phase III open-label trial found that roughly 80% of patients responding to the initial 50 mg course of zuranolone required no more than one further treatment in total across their participation in the one-year study. Four, in the WATERFALL phase III trial, zuranolone lowered depressive symptoms among patients with MDD, whether or not they had elevated anxiety. Five, zuranolone has demonstrated betterment of depressive symptoms in postpartum depression. Regarding zuranolone, we anticipate two phase III readouts during this year: the CORAL trial in MDD and the SKYLARK trial in PPD. Stroke is the next area I want to emphasize. We were thrilled last year by findings from the phase II trial of BIIB131, previously called TMS-007, in acute ischemic stroke. Giving the current standard of care pharmacological thrombolytic tPA is restricted to a brief therapeutic window of within four and a half hours after acute onset of stroke symptoms. That brief window exists to reduce the danger of intracranial hemorrhage, the adverse event of greatest concern tied to tPA; in the phase IIa trial of BIIB131, patients with acute stroke were randomized to get BIIB131 or placebo up to 12 hours from when they were last known to be normal. Safety served as the study's primary objective. Looking at the 52 patients treated with BIIB131, there were zero cases of symptomatic intracranial hemorrhage, whereas among the 38 patients given placebo, one such event occurred. That result held even though the treatment window was longer, with patients typically getting BIIB131 at 9.5 hours following the start of acute stroke symptoms. Also, on the Modified Rankin Scale, or mRS, which serves as a registrational endpoint for functional independence, BIIB131 delivered a statistically significant improvement relative to placebo. On top of that, among patients with a visible vessel occlusion, the rate of recanalization, meaning better vessel blood flow, came in at roughly 58% at 24 hours for those on BIIB131, versus 27% for those on placebo; our belief is that BIIB131 could potentially become a best-in-class thrombolytic for acute ischemic stroke by pushing the treatment time window out to 24 hours while maintaining a suitable efficacy and safety profile; right now we are assessing what the next development steps for BIIB131 should be. Beyond BIIB131, we are also continuing to move forward a phase III trial of BIIB093 in large hemispheric infarction, building on the mortality and cerebral edema effects seen in the phase II trial. Let me now shift to specialized immunology. In SLE we presently have two phase III assets, one being dapirolizumab pegol together with UCB, and the other being BIIB0 59, our anti-BDCA-2 antibody that was developed internally here at Biogen.

Priya Singhal

executive
#5

Each of these assets has the potential to be a first-in-class molecule for SLE. For cutaneous lupus erythematosus, or CLE, BIIB0 59 could also emerge as a first-in-class biologic. An autoimmune condition that impacts the skin, CLE may involve significant scarring as well as dyspigmentation. In the phase II LILAC study, the CLE portion also met its primary endpoint, demonstrating a dose response for BIIB0 59 regarding the percent change from baseline in the CLASI Activity Score — the standardized scale used to measure cutaneous CLE disease activity at week 16 among individuals with CLE. On top of that, among those given BIIB0 59, a higher CLASI 50 response rate showed up at week 16 — that is, a larger number of people hit a reduction of at least half versus where they started on the CLASI-A measure. With that data in hand, we intend to kick off a pivotal trial of BIIB0 59 for CLE during this year too. I'll move on now to ALS. ALS has been a key area of emphasis at Biogen for a long time, and the phase III VALOR results for tofersen continue to give us reason for optimism: the trial did not achieve its primary goal of a statistically significant shift in the ALSFRS from baseline to week 28, yet in our view there are signals that favor tofersen on a range of secondary and exploratory measures tied to biological and clinical activity. Data collection is ongoing in VALOR's open label extension, and enrollment is underway for the ATLAS presymptomatic study. A large number of SOD1 ALS patients have gained access to tofersen through the Global Expanded Access Program; that program operates in nations whose local regulations allow it, and our aim is to establish long-term access in those places. On top of that, we're collaborating with regulators to figure out what comes next for the program. Outside of the areas I just mentioned, Biogen continues to expand and diversify its R&D pipeline, which currently stands at 32 clinical programs. Among the newcomers: we've exercised our option with Ionis for BIIB 115, an investigational ASO that could allow for longer intervals between doses in SMA, and we've recently launched a phase I trial in Angelman syndrome — a rare genetic neurodevelopmental condition that impacts the nervous system, leading to serious physical and learning disabilities, with symptoms appearing in infancy. To start, I think 2022 is going to be a major year for what Biogen has in development, because there are so many significant data releases on the way. That includes the phase III trial of lecanemab in Alzheimer's disease, along with crucial results in neuropsychiatry — zuranolone for depression and BIIB 104 for schizophrenia — plus BIIB 78 in ALS. To wrap up, my view is that Biogen has built a broad collection of programs shaped by genetics, a thorough grasp of disease biology, focused expertise in specialized modalities, and digitalization. Because of that, I see Biogen as holding a distinct advantage when it comes to defining where neurology and specialized immunology treatments go next, and in improving the lives of patients along with the people who care for them. At this point, I'll hand things over to Mike.

Mike McDonnell

executive
#6

Thanks, Priya, and good morning to all of you. I appreciate you being here. My remarks will center on how we did in the fourth quarter, and I'll also talk a bit about the full year 2021. Fourth quarter total revenue came in at $2.7 billion, which was down 4% from the prior year on both an actual and a constant currency basis. For the full year, total revenue reached $11 billion, a decline of 18% compared with the prior year at actual currency and 19% at constant currency. That decrease was largely the result of generic competition for Tecfidera here in the United States. Non-GAAP diluted earnings per share for the fourth quarter came to $3.39. For the full year, non-GAAP diluted earnings per share was $19.22. Total MS revenue, which includes Ocrevus royalties, was $1.8 billion in the fourth quarter. Global Tecfidera revenue during the fourth quarter was $486 million. U.S. revenue was $161 million. For Tecfidera outside the U.S., revenue of $326 million was up 13% compared with the prior year, helped by 7% growth in underlying patients. Vumerity's global revenue in the fourth quarter was $125 million, versus $39 million in the fourth quarter of 2020. We anticipate that Vumerity will keep growing, both within the U.S. and beyond it. Tysabri's global revenue in the fourth quarter was $513 million, an increase of 8% from the prior year, aided by favorable channel dynamics in the U.S., and we were happy to see patient growth continue around the world. Now turning to SMA, global Spinraza revenue in the fourth quarter was $441 million, down 12% from the prior year. In the U.S., Spinraza revenue was $150 million, a decrease of 6% from the prior year, as competition continued to weigh on us; even so, we took encouragement from the fact that discontinuations eased somewhat relative to Q3 of this year. U.S. Spinraza revenue rose 7% from the prior quarter, including some favorable pricing and channel dynamics. Outside the U.S., Spinraza revenue was $291 million, down 14% from the prior year because of competition and pricing pressure. Our view remains that Spinraza can get back to growth over the medium to long-term. Total Aduhelm revenue in the fourth quarter was $1 million. Turning to our biosimilars business, fourth quarter revenue was $221 million, up 12% from the prior year, as higher volume was partly offset by pricing pressure. Our Q4 biosimilars revenue got a boost from a one-time price adjustment of roughly $10 million. Last week, we said that we had reached an agreement to sell our equity stake in our biosimilar joint venture, Samsung Bioepis, to Samsung Biologics for aggregate consideration of as much as $2.3 billion. Given that our cumulative investment in the joint venture was $727 million, we view this as an attractive financial return. It's worth noting that we will keep recording revenue and cost tied to the commercialization of Benepali, Imraldi, and Flixabi, with economics that will be largely the same as what you've seen before. We feel good about this deal because not only do we keep the commercialization rights we already hold, but going forward we'll also gain a broader capability to go after additional biosimilars products independently. We currently expect this transaction to close in mid-2022, subject to a securities registration statement filed by Samsung Biologics becoming effective and to certain regulatory and other customary closing conditions being met. Anti-CD20 revenue for the fourth quarter totaled $414 million, a 1% decline from the prior year. Rituxan brought in $153 million, down 29% year over year, driven by COVID-19's effects and ongoing erosion from biosimilar competition. Ocrevus royalty revenue came to $261 million, up 29% from the prior year. Keep in mind that the effective royalty rate on Ocrevus royalties resets every calendar year. Gross margin in the fourth quarter was 76% of revenue, compared with 83% in Q4 of 2020. The year-over-year gross margin decline was mainly attributable to a $164 million charge for Aduhelm inventory and purchase commitments above forecasted demand. Now let's move to expenses and the balance sheet. Non-GAAP R&D expense in Q4 was $700 million, which includes a $60 million opt-in payment to Ionis for BIIB115 and roughly $50 million in cost from exercising our option with Genentech for the bispecific antibody referenced earlier. For this program, we'll share in operating profits and losses in the low- to mid-30% range in the U.S. Non-GAAP SG&A came to $785 million, including approximately $155 million tied to Aduhelm. Eisai's reimbursement of roughly $45 million in U.S. SG&A costs shows up in the collaboration profit sharing line. Collaboration profit sharing in the fourth quarter lowered our net operating expense by $67 million, which reflects about $140 million of reimbursement from Eisai related to Aduhelm commercialization, partly offset by $75 million of net profit sharing expense from our collaboration with Samsung Bioepis. Our effective non-GAAP tax rate during Q4 of this year was about 17%. Over the course of 2021, we bought back roughly 6 million shares of our common stock for a total of $1.8 billion. We repurchased no shares during the fourth quarter of 2021. As of December 31st, 2021, $2.8 billion remained available under the share repurchase program authorized in October of 2020. Our weighted average diluted share count for the fourth quarter was approximately 147 million shares. During 2021, we produced approximately $3.6 billion in cash flow from operations. Capital expenditures came to $258 million, and free cash flow was about $3.4 billion. We closed the year with $7.3 billion in debt, $4.7 billion in cash and marketable securities, and $2.6 billion in net debt. Additionally, our $1 billion revolving credit facility was undrawn at year-end. All told, we continue to be in a very strong financial position, with substantial cash and financial capacity to grow the business over the long term. I'll now move to our full year guidance for 2022. For the complete 2022 fiscal year, we're projecting revenue in the range of $9.7 billion to $10 billion. Our financial outlook is built on the assumption that Aduhelm will contribute only minimal revenue during 2022, that Rituxan sales will keep falling because of biosimilar competition, and that Tecfidera revenue in the U.S. will continue to erode as generics enter the market. We're also assuming that Tecfidera generics could potentially arrive in the EU as soon as the first half of 2022, since it's hard to forecast how the ongoing challenges to Tecfidera market protection will play out; because of the reduced revenue from these high-margin products, we anticipate our gross margin percentage will come in lower than it did in 2021. For the full year 2022, we expect non-GAAP diluted EPS of between $14.25 and $16. Our guidance rests heavily on the final national coverage determination, which at this point remains uncertain. Should the final NCD, anticipated in April, turn out to be no broader than the draft NCD, our expected results and guidance could be affected. This guidance presumes no write-offs of Aduhelm inventory during 2022; that inventory was valued at roughly $225 million at the close of 2021. It also presumes reasonable utilization levels for the manufacturing capacity we've dedicated to our Alzheimer's disease programs. Should that manufacturing capacity go underutilized, we'd face incremental period costs that our guidance does not capture. We anticipate non-GAAP R&D expense of $2.2 billion-$2.3 billion and non-GAAP SG&A expense of $2.5 billion-$2.6 billion; the non-GAAP SG&A figure includes about $400 million to support the Aduhelm launch, roughly $145 million of which would be reimbursed by Eisai and appear in the collaboration profit-sharing line; these R&D and SG&A estimates factor in the cost reduction measures we previously disclosed, which should deliver about $500 million in annualized savings, with roughly $350 million of that expected to be realized during 2022. We expect to achieve those savings through a range of initiatives, potentially including downsizing our global Alzheimer's infrastructure — savings from which would be shared with Eisai — along with operating efficiency gains across SG&A and R&D. Those savings should be offset by roughly $200 million in additional investments in our pipeline and strategic initiatives. If the final NCD turns out to be no broader than the draft NCD, we anticipate pursuing further cost reduction measures, which our guidance does not reflect, to better align our cost base with our revenue base. Eisai would share in some of the savings from those additional cost reduction measures; we expect our non-GAAP tax rate for 2022 to fall between 15.5% and 16.5%, and we assume we'll use a portion of the remaining $2.8 billion share repurchase authorization over the course of the year, though that will hinge on various factors, including our business development activities. We've assumed foreign exchange rates as of December 31, 2021 will stay in effect throughout the year. When hedging is taken into account, we didn't factor in anything from possible acquisitions or major business development deals, since neither can be foreseen reliably, and we also left out any effects from possible changes to taxes or healthcare. At this point I'll hand things back to Michel so he can give his closing comments.

Michel Vounatsos

executive
#7

Thanks, Mike. So to wrap up, 2021 proved to be quite a busy year here at Biogen. Aduhelm has become the first therapy approved by the FDA that goes after a pathology that defines Alzheimer's disease. As everyone knows, this illness is complicated, and it's going to need ongoing research funding in the years ahead. Aduhelm represents a significant initial move, and our attention stays fixed on pushing forward our leading portfolio, aiming to do more to address what patients still lack. Our hope is that, in time, we can deliver further treatments with real impact, ones that take the scientific lessons from Aduhelm and go further — much like the successive waves of innovation we've witnessed in oncology. Prior to finishing, I want to mention how strongly Biogen is dedicated to corporate responsibility. The climate, health, and equity challenges are tightly linked and call for daring steps, which is why we're striving toward a world that's healthier, more sustainable, and fairer. Via our flagship program, Healthy Climate, Healthy Lives, along with other work, we're aiming to devise fresh approaches to business that make a positive difference in how we live and how we serve patients. It makes us proud that our leadership and openness on this front were recently acknowledged by the Dow Jones Sustainability World Index, Corporate Knights Global 100 and JUST 100. With this work, we intend to generate shareholder value by serving our patients, our employees, the environment, and the communities we're part of. To finish, I want to restate our dedication to talking with CMS and other stakeholders, hoping to identify a suitable route ahead so patients can access Aduhelm. At this point, we'll take questions on the call.

Robyn Karnauskas

analyst
#8

So, with that deal you recently completed involving Sangamo and Samsung, your cash position is now larger. Could you share a bit about what you're thinking regarding how that money could be put to work? Is it something like a near-term acquisition or other things you're considering, or does it simply provide you with optionality? Thanks.

Michel Vounatsos

executive
#9

Appreciate the question. As you're aware, our balance sheet is strong, and we keep examining ways to generate long-term shareholder value; right now we're actively pursuing certain business development opportunities aimed at enriching our pipeline and complementing our portfolio, consistent with our strategy. Each deal will be evaluated on its own merit, and that's the work we're doing.

Mike McDonnell

executive
#10

To build on what Robyn said, as we noted in our prepared remarks, this transaction is one we feel good about; against the capital we put in, it delivers a highly appealing return. Getting the deal to close will be priority number one. The release about the deal showed that proceeds will arrive gradually over time. Getting the deal to close would be priority number one, and we'll keep exploring, you know, every option we have when it comes to BD, transactions of every size. Our share buyback program will keep going as well. You know, the pipeline is still robust; we review a great many opportunities and, you know, our balance sheet is extremely healthy, as Michel said, and this will only leave it healthier.

Michel Vounatsos

executive
#11

Robyn, if I could just jump in here, one thing worth keeping in mind is that at this point, with our biosimilars portfolio, we're in a position to generate greater value. That means additional products, and additional geographies.

Michael Yee

analyst
#12

Thanks. Morning. So I suppose what I'm asking is this: when it comes to Aduhelm, what steps are you actively taking in an effort to get the NCD decision reversed? And once more, to restate it, if that decision isn't substantially revised, you folks would be inclined to trim costs even more. Could you describe what that would involve, and in what kind of situation that could shift? Say, for instance, if BAN2401 turned out positive. Perhaps just lay out the thinking and the roadmap for Aduhelm in 2022. Thanks.

Michel Vounatsos

executive
#13

Thanks, Mike. I'll begin, and after that my colleagues will jump in. To start, we factor in, very carefully, every one of the focus areas that CMS has set out. On that basis, we examine all the ongoing initiatives so as to address their question in a scientific manner, whether it concerns benefit-risk, concerns ARIA, or concerns disparity. There's plenty underway on our side, ranging from interventional studies, EMBARK and ENVISION in addition to the phase III. The moment has arrived, working alongside CMS, to embark on a wide-ranging set of real-world evidence initiatives that are already in motion, such as ICARE AD, though we're considering even more than that. That might include a disease registry and beyond. We're interacting with CMS in a constructive spirit, showing empathy, you know, to seek a way ahead that serves patients best. Alisha?

Alisha Alaimo

executive
#14

Absolutely. Michel, thanks for that. Michael, I appreciate the question. When it comes to the work our organization has been carrying out, over the last 3 weeks, we've sat down with CMS to present how we see things and to respond to whatever inquiries they might have. As you'll notice, we'll be filing our detailed feedback shortly, clearly within this current comment window. At the same time, we've been working to inform doctors, policymakers, and advocates regarding the real-world impact this could have on patients. As you've observed, plenty of people have been fairly bewildered by the draft NCD and by what CED truly entails for them. As you've probably noticed, a number of stakeholders have voiced comparable worries. We've witnessed patients, patient advocates, HCPs, additional manufacturers, and industry groups such as BIO and PhRMA likewise airing their views very openly. Only 1 week is left in the open comment period, and we eagerly anticipate the final decision coming in April so that the community gains greater clarity. That leads me to the comment period, where you might have noticed that, as of today, roughly 2,600 to 2,700 public comments have been sent to CMS, and once again, with 1 week still to go. I believe it matters for everyone to recall and bear in mind that CMS states on its website that comments citing published clinical evidence tend to be the most useful. Once you break out the comments from the dementia specialists, you'll find that a large number of them oppose this draft NCD. With earlier comment periods, we've observed that in the closing days, you generally see more letters that are thoroughly researched and heavily referenced. As I've mentioned previously, you'll see ours go up shortly. We stay actively involved with every stakeholder. We obviously stay involved with CMS as well, and we look forward to the final decision in April.

Mike McDonnell

executive
#15

Mike, regarding what you asked about the cost measures, as we mentioned in the remarks we prepared, our guidance does presume the final NCD would permit meaningful patient access over time. That won't turn into material revenue in 2022, though it would make access more open than the draft we saw. If that turns out not to be the situation, we're currently doing scenario planning around the cost measures. We brought up our plan for a $500 million cost measure, from which we estimate getting $350 million in 2022, and that's assumed in our guidance, and roughly $200 million of it will be invested across a variety of different initiatives, product launches included. Should we end up with a far more restrictive NCD, we will need to examine the elements of it. We will definitely be flexible when it comes to allocating resources between Aduhelm and lecanemab. As we mentioned in our SG&A, a $400 million Aduhelm support estimate is assumed, and we clearly would take a hard look at that, along with what other costs we could remove to offset any potential impacts on inventory, possible write-downs, and excess capacity charges, none of which are reflected in our guidance.

Michel Vounatsos

executive
#16

Mike, before we wrap up, one last point from me: our organization is absolutely dedicated to making sure this information comes through, both for the interventional trial and for the real-world studies. It's our view that generating data on this scale will be enough to settle whatever unresolved issue CMS has put forward.

Matthew Harrison

analyst
#17

Thanks, and good morning. I appreciate you taking my question. Could you provide some more detail about how Tecfidera's EU sales factor into your guidance, and what we might find out during this year? That would either tell us whether those revenues could be lost in 2022, or whether you might still count on them, which would mean possible upside relative to what you're currently projecting. Thank you.

Mike McDonnell

executive
#18

Of course, Matthew. Thanks for asking. We see a possibility that a generic could launch at some point during the first half of 2022. Our position is that we hold market protection rights, and we will definitely make every effort to defend them. As we said in our opening remarks and in our press release, our guidance does build in the assumption that some generic entry could occur at some point in the first half of 2022.

Michel Vounatsos

executive
#19

At the same time, this is driven by assumptions for tech, and as we've already shared, we're rolling out Vumerity across 20 markets in the EU.

Umer Raffat

analyst
#20

Hello everyone, and I appreciate you giving me the chance to ask something. I'd like to zero in on BAN2401 briefly, and there are really just a couple of things I want to raise. First, could you give us some sense of how large the problem of missed doses was in the phase III trial? My memory is that you added 200 patients to the sample size, and I'm curious whether that percentage growth relative to the initial sample size mirrors how many doses were missed. Second, regarding the primary analysis, will it be ITT, or will it exclude rapid progressors or particular patient subsets drawing on what was learned from Aduhelm? Thanks so much.

Michel Vounatsos

executive
#21

Priya?

Priya Singhal

executive
#22

Thanks for asking. To take a step back, I'd like to repeat that the readout for Clarity AD is coming in Q3 of this year, and our excitement about that result hasn't changed. On the specifics of the statistical analysis plan, I'm not in a position to say much. What I can share is this: whatever lessons could be folded in have been folded in, and the CDR-Sum of Boxes is still the primary endpoint. We're eager for that readout. Thank you.

Marc Goodman

analyst
#23

Yes, good morning. So, there are 2 important things coming up, correct? First, we're waiting for that CMS ruling, and second, clearly the lecanemab results are due in Q3. I'm just curious how you're thinking about this: if the first one turns out badly, would you make adjustments, or would you hold off until the lecanemab readout? Because, you know, we're all trying to figure out whether you'd dismantle the Alzheimer's organization ahead of receiving those results, and to what extent those 2 decisions are affecting how much business development you're doing. In other words, are you currently evaluating those BD possibilities no matter how either event turns out? Thanks.

Michel Vounatsos

executive
#24

Thank you for raising such a reasonable point. As I've said, our team will stay nimble and adaptable, and of course, we'll do whatever is necessary to protect our operating performance, all while executing the strategy. We do have confidence in lecanemab, but if the NCD stays in its present form, we'll take certain forceful measures.

Mike McDonnell

executive
#25

Marc, what I'd say in addition is that the share of our infrastructure going toward lecanemab as opposed to other things, and so on, hinges on what the final NCD actually states. It applies to the whole class, so it truly comes down to the details of the wording in that final NCD. As for BD, our BD work will keep going no matter what. It's continuous, and it never stops.

Salveen Richter

analyst
#26

Morning, and thank you for letting me ask. Given the opt-in we just saw for the Roche compound, is that a sign of a bigger structural push into oncology? And are there other spaces you're evaluating while you go after BD?

Michel Vounatsos

executive
#27

No — what I'd say is that this extends the excellent relationship we've had with Genentech going back to rituximab, and we've gained a remarkable cash flow contribution that all of us value, and that holds true even today, even with biosimilars in the picture. This is a continuation; it isn't a change in strategy. I laid out the four pillars of growth, and those stay our focus. By staying the course and delivering against them, we think we're positioned to create long-term shareholder value.

Cory Kasimov

analyst
#28

Morning, everyone. Appreciate you taking my question. I'd like to ask a follow-up regarding the phase III trial of lecanemab. Could you speak to how the patient population that was enrolled reflects sufficient representation of underrepresented communities, which might help address the CMS issues you mentioned? And regarding what Mike just said about the NCD and awaiting these results, wouldn't you expect that a final NCD might be revised if we later get strong positive phase III data from other Alzheimer's programs during the year? Thank you.

Michel Vounatsos

executive
#29

Priya?

Priya Singhal

executive
#30

Sure, I appreciate the question. On the underrepresented group and its percentage, I believe Eisai will offer a remark, yet the representation is genuinely quite strong, and the work done to bring that population into Clarity AD leaves us highly encouraged. As for what the NCD outcome means and the way it could affect lecanemab, my sense is that we still have to wait and find out. Right now this is a class situation — the NCD, as you know, is looking at the whole class — but we do think there is reason for optimism at the end of this path, and we're eager to learn the final result in April. Thank you.

Michel Vounatsos

executive
#31

My view is that every one of us needs to improve how we bring into interventional trials and real-world research those diverse populations that, sadly, carry a heavy burden of incidence for this disease. That is precisely our focus and our activity. My expectation and my hope is that CMS will respond positively to this; we made clear that with the ENVISION study, our target is to hit 16%-18% for the diverse population, and the same target applies in the real-world setting with ICARE AD. Going forward, we will collect considerably more data, and likewise for the additional real-world evidence opportunities that we are presenting to CMS.

Jay Olson

analyst
#32

Oh, hi there — appreciate the update, and thanks for taking my question. A self-administered sub-Q version of Aduhelm might be covered under Medicare Part D, which would put it beyond the reach of a possible CED should that get finalized, so could you share where Biogen currently stands on developing sub-Q Aduhelm? My understanding is that a bioequivalent study was run a few years back. Could sub-Q be an option in the relatively near term?

Michel Vounatsos

executive
#33

We'll certainly speak to that lifecycle management opportunity. Priya will offer a few remarks, but first let me lay out and return to the initial area of concern raised in the draft NCD — essentially benefit risk, along with questioning the hypothesis and the claims regarding modification and positive impact on patients; that, clearly, has nothing to do with any formulation. Priya.

Priya Singhal

executive
#34

Thanks for that question, and Michel, I appreciate the remarks; we'll certainly take what we learned previously from the Aduhelm subcutaneous formulation work and keep building on it, and right now we're in discussions with regulators to make sure there's a solid plan going forward for that development. That work is still underway. Thank you.

Geoff Meacham

analyst
#35

Morning, everybody. Jason here, filling in for Jeff. We really appreciate you taking our questions and the color. I was hoping to tie together some of what you said earlier regarding capital allocation. To be specific, what are the priorities, and what will ultimately determine the decision? Honestly, will it be the final NCD ruling that dictates how things get distributed, or are these activities continuing? Thank you.

Mike McDonnell

executive
#36

Yes, Jason, I appreciate the question. This is Mike. Just to restate part of what we've mentioned previously, we're always evaluating possibilities involving BD, transactions of every size, various opportunities, early stage, late stage, across the spectrum, you know, it covers everything, mainly centered on neuroscience, which is where our focus lies. We'll keep doing that, and we'll keep putting money into our pipeline, and that holds true no matter what happens with the NCD. It holds true regardless of the fact that we now have additional cash if we get the, you know, once the Samsung transaction closes. I believe we have a strong balance sheet that hasn't changed, $4.7 billion of cash and marketable securities at the end of the year, a modest amount of net debt, less than one turn; we have a billion-dollar revolver that's undrawn. We'll keep actively pursuing BD. That approach hasn't changed, and I don't foresee a major shift in strategy.

Michel Vounatsos

executive
#37

When it comes to what happens with NCD, or the Samsung transaction, or any other matter, we're going to keep actively looking at every option we have in the BD space, and that's what we're doing.

Brian Abrahams

analyst
#38

Hi, everyone. I really appreciate you fielding my question. Regarding lecanemab, I have just a few brief clarifications. Could you tell us whether COVID had any effect on gathering data for that trial? Given the NCD, do your intentions for accelerated filing for accelerated approval remain unchanged? If things go well, what changes to infrastructure might be necessary to handle dosing that happens more often compared with Aduhelm? Thank you.

Michel Vounatsos

executive
#39

Priya?

Priya Singhal

executive
#40

Appreciate you asking. Lecanemab remains on schedule to report results, and as we've said before, that readout is expected during the third quarter of 2022. Right now, we anticipate no shifts to that timing together with Eisai. That covers the first point. Next, I'd say there's nothing else of substance to share regarding the endpoints or the assessments incorporated into the trial. Is there something else I'm overlooking? All right.

Brian Abrahams

analyst
#41

Regarding how patients are being monitored after treatment given the pandemic, I realize this is a worldwide trial involving many locations.

Priya Singhal

executive
#42

Correct. In my view, the situation has been handled quite effectively, so my expectation is that the readouts will not face any postponements. Your next question, I believe, concerned accelerated approval. As you're aware, this product holds breakthrough designation, and a filing is going to happen. Filing is what we intend to do. When it comes to the filing, numerous parts have already been submitted, and communication will occur once that filing is finished. The key point to keep in mind, I believe, is that although it may be submitted as an accelerated filing, the confirmatory trial for lecanemab is Clarity AD, which is set to produce results within this year. My expectation is that the Clarity AD confirmatory trial will yield its readout while this program is under review. I trust that makes things clear.

Michel Vounatsos

executive
#43

Let me just restate that we and Eisai are collaborating quite tightly to identify ways our respective organizations’ strengths can complement each other, and to determine how the value of both compounds can best be maximized.

Salim Syed

analyst
#44

Thanks a lot for taking the question, everyone. Michel, I feel like I should bring up the elephant in the room here. I'm asking this in a constructive spirit, and I hope that comes across; so clearly, when there's talk about, you know, a disconnect between management and the board over at Biogen, and BD is obviously a major priority for you folks, and I appreciate all the remarks that you're evaluating deals across every size, early stage as well as late stage. From where you sit, does a misalignment exist that would make meaningful BD hard to pull off in 2022? Has anything shifted such that we can now expect that to happen? Many thanks.

Michel Vounatsos

executive
#45

Salim, thank you for offering me the chance to respond to this. I'd encourage you to examine every BD deal that got done over the last five years against the five years before that. That should give you a sense of the alignment, though that doesn't imply the path is simple. It means we face challenges as management. There's a real need for candid conversation involving the board and management, you know, to ensure we're positioned as well as possible to allocate capital. We managed, and we still manage, to collaborate so the organization can advance into the strongest strategic position, which is where we think we sit now relative to the earlier period. Consider the four pillars of growth. Consider what we're doing in biosimilars. We're expanding the chance to generate cash flow. Despite being in the regrettable position of losing Rituxan and Tecfidera along with a launch pushed back by nearly a year in the end, assuming NCD turns out positive for Aduhelm, we still have a multi-billion cash flow generation opportunity; we work alongside each other very closely. Thank you all for this strong engagement. I truly want to restate that we remain committed to engaging with CMS and every other stakeholder, hoping to identify a suitable path toward immediate patient access to Aduhelm. Thank you all for your attention today.

Operator

operator
#46

This concludes today's call. Thank you all for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.